Trial · NCT03037385
Adverse event totals12
The totals the trial posted for each group.
1 to 12 of 12
Download this page as JSON| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pralsetinib ≤ 300 mg QD | 15 | 37 |
| Total, all-cause mortality | Pralsetinib 400 mg QD | 245 | 540 |
| Total, all-cause mortality | Pralsetinib BID Dosing Schedule | 7 | 9 |
| Total, all-cause mortality | Pralsetinib All Doses | 268 | 590 |
| Total, other adverse events | Pralsetinib ≤ 300 mg QD | 36 | 37 |
| Total, other adverse events | Pralsetinib 400 mg QD | 536 | 540 |
| Total, other adverse events | Pralsetinib BID Dosing Schedule | 9 | 9 |
| Total, other adverse events | Pralsetinib All Doses | 585 | 590 |
| Total, serious adverse events | Pralsetinib ≤ 300 mg QD | 26 | 37 |
| Total, serious adverse events | Pralsetinib 400 mg QD | 381 | 540 |
| Total, serious adverse events | Pralsetinib BID Dosing Schedule | 7 | 9 |
| Total, serious adverse events | Pralsetinib All Doses | 416 | 590 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03037385/event-totals